endometriosis and adenomyosis
Conditions
Interventions
1:2.5mg qd
2:5mg qd
3:25mg qw
Sponsors
Women's Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) female, aged >=18, menstruating,agree to the RU - 486 treatment and signed informed consent; (2) the preoperative vaginal ultrasound and/or nuclear magnetic resonance (MRI) confirmed as a diffuse wall after the front wall of the uterus, and/or glandular myopathy, cause myometrium diffuse thickening obviously; (3) severe dysmenorrhea or with menorrhagia; (4) placed separately LNG-IUS invalid or failure, including oral contraceptive drugs; (5) requires the uterus or fertility; (6) 3 months before drug treatment, did not accept other hormonal drug therapy for adenomyosis.
Exclusion criteria
Exclusion criteria: 1. participating in other clinical trials of patients; 2. the researchers think the other reasons are not suitable for clinical subjects, as follows: (1) the endometrium cervical breast malignant diseases; (2) with serious heart, liver, kidney function disorder and so on; (3) according to the researchers evaluation, the existing patients may as a result of the drug treatment and disease; (4) pregnancy or lactation in the three months before the start of treatment had childbirth, abortion or lactation); (5) going to pregnancy within the established treatment period or give birth,miscarriage, lactation 3 months before treatment; (6) body mass index (BMI) > 30 kg/m2; (7) allergic to study drug ingredients; (8) Combination using other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain;menstrual amount;the volume of uterus;CA125;hemoglobin;endometrial thickness; | — |
Countries
China
Contacts
Public ContactXinmei Zhang
Women's Hospital School Of Medicine Zhejiang University
Outcome results
None listed